Abstract
Psoriatic arthritis (PsA) is a chronic, complex, inflammatory arthritis that, when left untreated, can lead to erosions, deformities and decrease in quality of life. PsA is known to be associated with multiple comorbidities, including cardiovascular, metabolic and mental health syndromes, all of which can increase its overall morbidity and mortality. Here we describe a cohort of patients with PsA from an urban, tertiary care, and followed at a combined rheumatology-dermatology center. Depression was reported in 22.8% of the population, anxiety in 18%, and attention deficit hyperactivity disorder in 4%. Depression was more common in female participants (p<.001). At baseline, individuals with PsA and concomitant depression had similar tender and swollen joint counts and RAPID3 compared to those without depression, and had lower body surface area affected by psoriasis (p=.04). At year one, all patients had improvement in clinical outcomes. However, patients with depression had a significantly higher tender joint count compared to those without depression (p=.001), despite similar swollen joint count and body surface area. These observations underscore the importance of addressing depression and psychological distress as part of PsA treatment outcomes and points towards the need to address residual pain through co-adjuvant approaches.
Competing Interest Statement
RHH has served as a consultant for Janssen. ALN declares that she has served as a consultant for Janssen, UCB, AbbVie, BMS and her immediate family member owns shares of stock in J&J, Eli Lilly, AbbVie, and Pfizer. SR has served as a consultant for AbbVie/Abbott, Amgen, Novartis, Janssen, Pfizer. SA has received grants from Johnson and Johnson. JUS has served as a consultant for Janssen, Novartis, Pfizer, Sanofi, Amgen, UCB and AbbVie; and has received funding for investigator-initiated studies from Janssen and Pfizer.
Funding Statement
This study was funded by NIH/NIAMS (R01AR074500 to Scher, T32-AR-069515 to Haberman, Scher), Rheumatology Research Foundation, the National Psoriasis Foundation, The Beatrice Snyder Foundation, The Riley Family Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approved by New York Langone Institutional Review Board (s20-00084)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclosures: RHH has served as a consultant for Janssen. ALN declares that she has served as a consultant for Janssen, UCB, AbbVie, BMS and her immediate family member owns shares of stock in J&J, Eli Lilly, AbbVie, and Pfizer. SR has served as a consultant for AbbVie/Abbott, Amgen, Novartis, Janssen, Pfizer. SA has received grants from Johnson and Johnson. JUS has served as a consultant for Janssen, Novartis, Pfizer, Sanofi, Amgen, UCB and AbbVie; and has received funding for investigator-initiated studies from Janssen and Pfizer.
Funding: This study was funded by NIH/NIAMS (R01AR074500 to Scher, T32-AR-069515 to Haberman, Scher), Rheumatology Research Foundation, the National Psoriasis Foundation, The Beatrice Snyder Foundation, The Riley Family Foundation.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
